Charles River Laboratories International, Inc. — Company profile
Healthcare · Diagnostics & Research · United States
Last price 359.41 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 17.16B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Details
| Name | Charles River Laboratories International, Inc. |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 19700 |
| Founded | 1947 |
| Ipo Date | 2000-06-23 |
| Ceo | Birgit Girshick |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US1598641074 |
| Cusip | 159864107 |
| Cik | 0001100682 |
| Sic | 8731 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Birgit Girshick | Chief Executive Officer and Director |
| Michael Gunnar Knell | Corporate Senior Vice President and Chief Accounting Officer |
| Joseph W. LaPlume J.D. | Corporate Executive Vice President of Corporate Development and Strategy |
| Victoria L. Creamer | Corporate Executive Vice President and Chief People Officer |
| Glenn G. Coleman CPA | Corporate Executive Vice President and Chief Financial Officer |
| Mark Mintz | Corporate EVice President, Chief Information Officer and Global Shared Services |
| Todd Spencer | Corporate Vice President of Investor Relations |
| Kerry Dailey | Corporate Senior Vice President and Chief Legal Officer |
| Amy E. Cianciaruso | Corporate Senior Vice President, Chief Communications Officer and Government Relations |
| Dr. Brian F. Bathgate Ph.D. | Corporate Senior Vice President of European Safety Assessment |
Contact
| Address | 251 Ballardvale Street, Wilmington, Massachusetts 01887, United States |
| Phone | 781 222 6000 |
| Website | https://www.criver.com |